Sections

Home | Brain and Nerves | Brain Diseases | Alzheimer’s

Alzheimer’s

New imaging technique in Alzheimer’s disease - opens up possibilities for new drug development

Tau PET is a new and promising imaging method for Alzheimer’s disease. A case study from Lund University in Sweden now confirms ...

Why does Alzheimer’s disease affect more women than men?

Supported by a new grant from the Alzheimer’s Association, USC researcher explores a key Alzheimer’s gene and how it disproportionately impacts women ...

The shape-shifting protein behind Alzheimer’s disease

New research shows how amyloid beta enters brain cells ... Full story

Poison in the brain

The following factors facilitate the formation of putatively toxic structures in the neuronal nuclei of Alzheimer’s patients. ... Full story

Memory Loss Not Enough to Diagnose Alzheimer’s

Alzheimer’s disease can have symptoms other than memory loss ... Full story

New strategy to obtain a specific type of amyloid-beta aggregate that may underlie neuronal death in Alzheimer’s disease

Researchers at IRB Barcelona describe for the first time how to prepare a specific type of aggregate of the amyloid-beta protein with the ability to perforate the cell membrane. What causes neuron death and the subsequent cognitive decline in Alzheimer´s disease is still unknown. ... Full story

Efficacy and Safety of Crocus Sativus L in Patients with Mild Cognitive Impairment: One Year Single-Blind Randomized, with Parallel Groups, Clinical Trial.

Greek researchers and clinicians demonstrated the potential of Crocus Sativus L. (saffron) as a therapeutic pharmaceutical natural compound for older adults with amnestic Mild Cognitive Impairment (aMCI). MCI is a condition that often predates Alzheimer’s disease (AD) and is characterized by memory loss and inability to execute complex Activities of Daily Living. While there is no treatment for MCI and symptomatic only treatment for AD, the global effort against cognitive disorders is focused on early detection and management of AD at the stage of MCI. ... Full story

Markers associated with Alzheimer’s and Parkinson’s diseases are present in Mexico City children chronically exposed to concentrations of fine particulate matter PM2.5 above the current EPA USA standards

A new study by researchers at the Universities of Montana, Valle de México, Boise State, Veracruz University, Médica Sur, Centro de Ciencias de la Atmósfera, UNAM, Hospital Regional de Alta Especialidad, Ciudad Victoria, Hospital de Especialidades #14, IMSS, Centre Hospitalier Universitaire, Hôpital de Hautepierre and AJ Roboscreen GmbH heightens concerns over the detrimental impact of fine particulate matter PM2.5 on CSF markers associated with Alzheimer and Parkinson’s diseases in children ages 11.9±4.8 years. These findings are published in the Journal of Alzheimer’s Disease. ... Full story

Subjective Cognitive Decline and risk of future AD dementia – results from a German multi-center study highlights the importance of temporal consistency

A new study, based on longitudinal data from the German Study on Aging, Cognition and Dementia in Primary Care Patients (AgeCoDe), suggests that temporal stability versus instability of an individual’s report of subjective worsening of cognition over time plays an important role with regard to whether such experiences are associated with future dementia risk. These findings, which will be published in the Journal of Alzheimer's Disease 54(3), add to a constantly growing strand of research on the phenomenon of “Subjective Cognitive Decline” (SCD) in Alzheimer’s Disease (AD). ... Full story

Major step towards Alzheimer’s blood test

A research team, led by Cardiff University, has made a significant step towards the development of a simple blood test to predict the onset of Alzheimer’s disease. ... Full story

1 2 3 4 5 6 7 8 9 10 next last total: 534 | displaying: 1 - 10